Found 582 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Evaluating Changes in Perfusion to the Chest Wall During Cardiothoracic Surgery
The research study is being conducted to learn how violating the chest wall during Cardiothoracic surgery changes perfusion to the bone and soft tissue of the chest wall. Further, this study will investigate whether changes in perfusion are correlated with adverse clinical outcomes. If you agree to join the study, …
Boomerang Early Feasibility Study
The purpose of this research study is to learn more about the safety and performance of SNS when used in patients who have Crohn’s disease or left-sided ulcerative colitis. The InterStim™ Neurostimulator (InterStim) will be used in every participant who agrees to participate and meets all the eligibility criteria for …
EVALUATING THE UPTAKE OF [18F] FLUOROESTRADIOL (FES) BPET/DBT IN PRIMARY BREAST CANCER TO MEASURE THE LOCALIZED EXTENT OF ESTROGEN RECEPTOR POSITIVE DISEASE
The purpose of this study is to test a new scanner device that combines two types of imaging called Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DPT) for imaging of a radioactive imaging drug called 18F-Fluoroestradiol (FES), as a diagnostic device for imaging estrogen receptor (ER) positive breast …
Study to Investigate Oral Brepocitinib in Adults with Dermatomyositis
This research study is being done to investigate how safe and effective the investigational drug brepocitinib is for treating dermatomyositis. If you agree to join the study, you will be asked to complete the following research procedures: • signing this informed consent • having reviews of your medical/health history and …
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study …
NONCOMPACT- International Consortium for Multimodality Phenotyping in Adults with Non-compaction
This is a prospective, multicenter observational study to identify clinical, genetic and imaging predictors of clinical outcome in patients with suspected non-compaction cardiomyopathy Many healthy people have increased trabeculations without consequences, however, some may develop blood clots, heart rhythm disorders or heart failure later in life. Currently we cannot predict …
Parkinsons Foundation PD GENEration Genetic Registry
This study aims to collect and share Parkinson’s disease genetic testing data from up to 500,000 study participants for research use. Participants will include people with Parkinson's disease (PD) and people at-risk for developing PD, and members of the general community that do not have PD. To investigate the genetic …
A Prospective Multicenter Non-Blinded Non-Randomized Study of the Relay PRO Thoracic Stent-Graft in Subjects with Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
The primary safety objective is a composite of the number of Major Adverse Events (MAEs) occurring through 30 days post-procedure compared to the rate in subjects treated with the Relay Thoracic Stent-Graft in the U.S. Pivotal Trial (P110038). The primary effectiveness objective is a composite of the number of effectiveness …
PILOT STUDY TO ASSESS LUNG FUNCTION USING PERFUSION BLOOD VOLUME DUAL ENERGY CT AND 4DCT DERIVED LUNG VENTILATION IMAGING
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
MG0004: A randomized open-label extension study to investigate the long-term safety tolerability and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis
Rozanolixizumab is a humanized IgG4 monoclonal antibody that is being developed as an inhibitor of the activity of the neonatal Fc receptor (FcRn) for IgG. By blocking the activity of neonatal FcRn, rozanolixizumab accelerates the catabolism of antibodies and reduces the serum IgG concentration, including pathogenic IgG in MG patients, …
Please choose between Voice or SMS based delivery of verification code
or